{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:42:08Z","timestamp":1793032928645,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T00:00:00Z","timestamp":1683936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T00:00:00Z","timestamp":1683936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The hepatotoxicity of regorafenib is one of the most noteworthy concerns for patients, however the mechanism is poorly understood. Hence, there is a lack of effective intervention strategies. Here, by comparing the target with sorafenib, we show that regorafenib-induced liver injury is mainly due to its nontherapeutic target Eph receptor A2 (EphA2). EphA2 deficiency attenuated liver damage and cell apoptosis under regorafenib treatment in male mice. Mechanistically, regorafenib inhibits EphA2 Ser897 phosphorylation and reduces ubiquitination of p53 by altering the intracellular localization of mouse double minute 2 (MDM2) by affecting the extracellular signal-regulated kinase (ERK)\/MDM2 axis. Meanwhile, we found that schisandrin C, which can upregulate the phosphorylation of EphA2 at Ser897 also has protective effect against the toxicity in vivo. Collectively, our findings identify the inhibition of EphA2 Ser897 phosphorylation as a key cause of regorafenib-induced hepatotoxicity, and chemical activation of EphA2 Ser897 represents a potential therapeutic strategy to prevent regorafenib-induced hepatotoxicity.<\/jats:p>","DOI":"10.1038\/s41467-023-38430-8","type":"journal-article","created":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T06:02:28Z","timestamp":1683957748000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK\/MDM2\/p53 axis"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0578-7212","authenticated-orcid":false,"given":"Hao","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wentong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhuai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangxin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1896-097X","authenticated-orcid":false,"given":"Zhifei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaojun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6576-2052","authenticated-orcid":false,"given":"Peihua","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,13]]},"reference":[{"key":"38430_CR1","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1517\/13543784.2012.684752","volume":"21","author":"D Strumberg","year":"2012","unstructured":"Strumberg, D. & Schultheis, B. Regorafenib for cancer. Expert Opin. Investig. Drugs 21, 879\u2013889 (2012).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"38430_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-021-00254-5","volume":"7","author":"JY Blay","year":"2021","unstructured":"Blay, J. Y., Kang, Y. K., Nishida, T. & von Mehren, M. Gastrointestinal stromal tumours. Nat. Rev. Dis. Prim. 7, 22 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"38430_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix, J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389, 56\u201366 (2017).","journal-title":"Lancet"},{"key":"38430_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nrclinonc.2016.214","volume":"14","author":"D Killock","year":"2017","unstructured":"Killock, D. Liver cancer: Regorafenib - a new RESORCE in HCC. Nat. Rev. Clin. Oncol. 14, 70\u201371 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"38430_CR5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jhep.2018.04.010","volume":"69","author":"RS Finn","year":"2018","unstructured":"Finn, R. S. et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial. J. Hepatol. 69, 353\u2013358 (2018).","journal-title":"J. Hepatol."},{"key":"38430_CR6","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.jhep.2018.05.034","volume":"69","author":"M Tong","year":"2018","unstructured":"Tong, M. et al. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib. J. Hepatol. 69, 826\u2013839 (2018).","journal-title":"J. Hepatol."},{"key":"38430_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"GD Demetri","year":"2013","unstructured":"Demetri, G. D. et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 295\u2013302 (2013).","journal-title":"Lancet"},{"key":"38430_CR8","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","volume":"16","author":"J Li","year":"2015","unstructured":"Li, J. et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 16, 619\u2013629 (2015).","journal-title":"Lancet Oncol."},{"key":"38430_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381, 303\u2013312 (2013).","journal-title":"Lancet"},{"key":"38430_CR10","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.cell.2009.04.037","volume":"137","author":"KH Vousden","year":"2009","unstructured":"Vousden, K. H. & Prives, C. Blinded by the light: the growing complexity of p53. Cell 137, 413\u2013431 (2009).","journal-title":"Cell"},{"key":"38430_CR11","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2005.04.018","volume":"43","author":"C Eipel","year":"2005","unstructured":"Eipel, C. et al. Pifithrin-alpha induced p53 inhibition does not affect liver regeneration after partial hepatectomy in mice. J. Hepatol. 43, 829\u2013835 (2005).","journal-title":"J. Hepatol."},{"key":"38430_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jhep.2012.08.008","volume":"58","author":"RE Castro","year":"2013","unstructured":"Castro, R. E. et al. miR-34a\/SIRT1\/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J. Hepatol. 58, 119\u2013125 (2013).","journal-title":"J. Hepatol."},{"key":"38430_CR13","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.jhep.2009.12.040","volume":"52","author":"S Chen","year":"2010","unstructured":"Chen, S. et al. p53-insensitive PUMA down-regulation is essential in the early phase of liver regeneration after partial hepatectomy in mice. J. Hepatol. 52, 864\u2013871 (2010).","journal-title":"J. Hepatol."},{"key":"38430_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36208-3","volume":"8","author":"H Shi","year":"2018","unstructured":"Shi, H. et al. Deficiency of apoptosis-stimulating protein two of p53 promotes liver regeneration in mice by activating mammalian target of rapamycin. Sci. Rep. 8, 17927 (2018).","journal-title":"Sci. Rep."},{"key":"38430_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jhep.2010.08.007","volume":"54","author":"Z Derdak","year":"2011","unstructured":"Derdak, Z. et al. Activation of p53 enhances apoptosis and insulin resistance in a rat model of alcoholic liver disease. J. Hepatol. 54, 164\u2013172 (2011).","journal-title":"J. Hepatol."},{"key":"38430_CR16","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.jhep.2012.11.042","volume":"58","author":"Z Derdak","year":"2013","unstructured":"Derdak, Z. et al. Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J. Hepatol. 58, 785\u2013791 (2013).","journal-title":"J. Hepatol."},{"key":"38430_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0507-z","volume":"9","author":"J Sun","year":"2018","unstructured":"Sun, J. et al. p53 attenuates acetaminophen-induced hepatotoxicity by regulating drug-metabolizing enzymes and transporter expression. Cell Death Dis. 9, 536 (2018).","journal-title":"Cell Death Dis."},{"key":"38430_CR18","doi-asserted-by":"publisher","first-page":"F1140","DOI":"10.1152\/ajprenal.00262.2004","volume":"287","author":"M Jiang","year":"2004","unstructured":"Jiang, M., Yi, X., Hsu, S., Wang, C. Y. & Dong, Z. Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity. Am. J. Physiol. Ren. Physiol. 287, F1140\u2013F1147 (2004).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"38430_CR19","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1373\/clinchem.2003.026849","volume":"50","author":"C Hafner","year":"2004","unstructured":"Hafner, C. et al. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin. Chem. 50, 490\u2013499 (2004).","journal-title":"Clin. Chem."},{"key":"38430_CR20","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3390\/genes4030334","volume":"4","author":"JE Park","year":"2013","unstructured":"Park, J. E., Son, A. I. & Zhou, R. Roles of EphA2 in development and disease. Genes 4, 334\u2013357 (2013).","journal-title":"Genes"},{"key":"38430_CR21","doi-asserted-by":"publisher","first-page":"e1000584","DOI":"10.1371\/journal.pgen.1000584","volume":"5","author":"G Jun","year":"2009","unstructured":"Jun, G. et al. EPHA2 is associated with age-related cortical cataract in mice and humans. PLoS Genet 5, e1000584 (2009).","journal-title":"PLoS Genet"},{"key":"38430_CR22","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1242\/dev.100727","volume":"140","author":"C Cheng","year":"2013","unstructured":"Cheng, C., Ansari, M. M., Cooper, J. A. & Gong, X. EphA2 and Src regulate equatorial cell morphogenesis during lens development. Development 140, 4237\u20134245 (2013).","journal-title":"Development"},{"key":"38430_CR23","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1083\/jcb.200304018","volume":"162","author":"H Miao","year":"2003","unstructured":"Miao, H. et al. EphA kinase activation regulates HGF-induced epithelial branching morphogenesis. J. Cell Biol. 162, 1281\u20131292 (2003).","journal-title":"J. Cell Biol."},{"key":"38430_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2009.04.009","volume":"16","author":"H Miao","year":"2009","unstructured":"Miao, H. et al. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 16, 9\u201320 (2009).","journal-title":"Cancer Cell"},{"key":"38430_CR25","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1111\/liv.13217","volume":"36","author":"A Sacre","year":"2016","unstructured":"Sacre, A. et al. Regorafenib induced severe toxic hepatitis: characterization and discussion. Liver Int. 36, 1590\u20131594 (2016).","journal-title":"Liver Int."},{"key":"38430_CR26","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.3892\/or.2016.5328","volume":"37","author":"JJ Tsai","year":"2017","unstructured":"Tsai, J. J., Pan, P. J. & Hsu, F. T. Regorafenib induces extrinsic and intrinsic apoptosis through inhibition of ERK\/NF-kappaB activation in hepatocellular carcinoma cells. Oncol. Rep. 37, 1036\u20131044 (2017).","journal-title":"Oncol. Rep."},{"key":"38430_CR27","first-page":"4919","volume":"37","author":"FT Hsu","year":"2017","unstructured":"Hsu, F. T. et al. Regorafenib induces apoptosis and inhibits metastatic potential of human bladder carcinoma cells. Anticancer Res. 37, 4919\u20134926 (2017).","journal-title":"Anticancer Res."},{"key":"38430_CR28","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1158\/1078-0432.CCR-13-2944","volume":"20","author":"D Chen","year":"2014","unstructured":"Chen, D., Wei, L., Yu, J. & Zhang, L. Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis. Clin. Cancer Res. 20, 3472\u20133484 (2014).","journal-title":"Clin. Cancer Res."},{"key":"38430_CR29","doi-asserted-by":"publisher","first-page":"5768","DOI":"10.1158\/1078-0432.CCR-14-0725","volume":"20","author":"WT Tai","year":"2014","unstructured":"Tai, W. T. et al. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma. Clin. Cancer Res. 20, 5768\u20135776 (2014).","journal-title":"Clin. Cancer Res."},{"key":"38430_CR30","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/jat.3551","volume":"38","author":"C Mingard","year":"2018","unstructured":"Mingard, C., Paech, F., Bouitbir, J. & Krahenbuhl, S. Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines. J. Appl. Toxicol. 38, 418\u2013431 (2018).","journal-title":"J. Appl. Toxicol."},{"key":"38430_CR31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.tox.2018.01.005","volume":"395","author":"F Paech","year":"2018","unstructured":"Paech, F. et al. Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells. Toxicology 395, 34\u201344 (2018).","journal-title":"Toxicology"},{"key":"38430_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41580-019-0173-8","volume":"21","author":"FJ Bock","year":"2020","unstructured":"Bock, F. J. & Tait, S. W. G. Mitochondria as multifaceted regulators of cell death. Nat. Rev. Mol. Cell Biol. 21, 85\u2013100 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"38430_CR33","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrm3352","volume":"13","author":"E Sahin","year":"2012","unstructured":"Sahin, E. & DePinho, R. A. Axis of ageing: telomeres, p53 and mitochondria. Nat. Rev. Mol. Cell Biol. 13, 397\u2013404 (2012).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"38430_CR34","first-page":"145","volume":"9","author":"JD Amaral","year":"2010","unstructured":"Amaral, J. D., Xavier, J. M., Steer, C. J. & Rodrigues, C. M. The role of p53 in apoptosis. Disco. Med. 9, 145\u2013152 (2010).","journal-title":"Disco. Med."},{"key":"38430_CR35","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0006-2952(99)00153-7","volume":"58","author":"MR Bennett","year":"1999","unstructured":"Bennett, M. R. Mechanisms of p53-induced apoptosis. Biochem. Pharm. 58, 1089\u20131095 (1999).","journal-title":"Biochem. Pharm."},{"key":"38430_CR36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41580-019-0110-x","volume":"20","author":"A Hafner","year":"2019","unstructured":"Hafner, A., Bulyk, M. L., Jambhekar, A. & Lahav, G. The multiple mechanisms that regulate p53 activity and cell fate. Nat. Rev. Mol. Cell Biol. 20, 199\u2013210 (2019).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"38430_CR37","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.bbcan.2017.08.001","volume":"1868","author":"SK Kwon","year":"2017","unstructured":"Kwon, S. K., Saindane, M. & Baek, K. H. p53 stability is regulated by diverse deubiquitinating enzymes. Biochim. Biophys. Acta Rev. Cancer 1868, 404\u2013411 (2017).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"38430_CR38","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1080\/15548627.2018.1501134","volume":"14","author":"P Luo","year":"2018","unstructured":"Luo, P. et al. HMGB1 represses the anti-cancer activity of sunitinib by governing TP53 autophagic degradation via its nucleus-to-cytoplasm transport. Autophagy 14, 2155\u20132170 (2018).","journal-title":"Autophagy"},{"key":"38430_CR39","doi-asserted-by":"crossref","unstructured":"Ettrich, T. J. & Seufferlein, T. Regorafenib. Recent Results Cancer Res. 211, 45\u201356 (2018).","DOI":"10.1007\/978-3-319-91442-8_3"},{"key":"38430_CR40","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1248\/bpb.b17-00446","volume":"40","author":"Y Zhou","year":"2017","unstructured":"Zhou, Y. & Sakurai, H. Emerging and diverse functions of the EphA2 noncanonical pathway in cancer progression. Biol. Pharm. Bull. 40, 1616\u20131624 (2017).","journal-title":"Biol. Pharm. Bull."},{"key":"38430_CR41","doi-asserted-by":"publisher","first-page":"16017","DOI":"10.1074\/jbc.M709934200","volume":"283","author":"WB Fang","year":"2008","unstructured":"Fang, W. B., Brantley-Sieders, D. M., Hwang, Y., Ham, A. J. & Chen, J. Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase. J. Biol. Chem. 283, 16017\u201316026 (2008).","journal-title":"J. Biol. Chem."},{"key":"38430_CR42","doi-asserted-by":"publisher","first-page":"42375","DOI":"10.1074\/jbc.M503786200","volume":"280","author":"M Tanaka","year":"2005","unstructured":"Tanaka, M., Kamata, R. & Sakai, R. EphA2 phosphorylates the cytoplasmic tail of Claudin-4 and mediates paracellular permeability. J. Biol. Chem. 280, 42375\u201342382 (2005).","journal-title":"J. Biol. Chem."},{"key":"38430_CR43","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/387296a0","volume":"387","author":"Y Haupt","year":"1997","unstructured":"Haupt, Y., Maya, R., Kazaz, A. & Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 387, 296\u2013299 (1997).","journal-title":"Nature"},{"key":"38430_CR44","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/ncb1101-973","volume":"3","author":"BP Zhou","year":"2001","unstructured":"Zhou, B. P. et al. HER-2\/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 3, 973\u2013982 (2001).","journal-title":"Nat. Cell Biol."},{"key":"38430_CR45","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1002\/hep.26253","volume":"57","author":"XD Cui","year":"2013","unstructured":"Cui, X. D. et al. Activation of mammalian target of rapamycin complex 1 (mTORC1) and Raf\/Pyk2 by growth factor-mediated Eph receptor 2 (EphA2) is required for cholangiocarcinoma growth and metastasis. Hepatology 57, 2248\u20132260 (2013).","journal-title":"Hepatology"},{"key":"38430_CR46","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1074\/jbc.M604953200","volume":"282","author":"M Malmlof","year":"2007","unstructured":"Malmlof, M., Roudier, E., Hogberg, J. & Stenius, U. MEK-ERK-mediated phosphorylation of Mdm2 at Ser-166 in hepatocytes. Mdm2 is activated in response to inhibited Akt signaling. J. Biol. Chem. 282, 2288\u20132296 (2007).","journal-title":"J. Biol. Chem."},{"key":"38430_CR47","doi-asserted-by":"publisher","first-page":"28962","DOI":"10.1074\/jbc.272.46.28962","volume":"272","author":"R Yu","year":"1997","unstructured":"Yu, R., Tan, T. H. & Kong, A. N. Butylated hydroxyanisole and its metabolite tert-butylhydroquinone differentially regulate mitogen-activated protein kinases. The role of oxidative stress in the activation of mitogen-activated protein kinases by phenolic antioxidants. J. Biol. Chem. 272, 28962\u201328970 (1997).","journal-title":"J. Biol. Chem."},{"key":"38430_CR48","doi-asserted-by":"publisher","first-page":"152760","DOI":"10.1016\/j.phymed.2018.11.020","volume":"59","author":"P Zhu","year":"2019","unstructured":"Zhu, P., Li, J., Fu, X. & Yu, Z. Schisandra fruits for the management of drug-induced liver injury in China: a review. Phytomedicine. 59, 152760 (2019).","journal-title":"Phytomedicine."},{"key":"38430_CR49","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13287-021-02152-9","volume":"12","author":"M Jin","year":"2021","unstructured":"Jin, M. et al. Advancements in stem cell-derived hepatocyte-like cell models for hepatotoxicity testing. Stem Cell Res. Ther. 12, 84 (2021).","journal-title":"Stem Cell Res. Ther."},{"key":"38430_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0553-2","volume":"14","author":"IJ Onakpoya","year":"2016","unstructured":"Onakpoya, I. J., Heneghan, C. J. & Aronson, J. K. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 14, 10 (2016).","journal-title":"BMC Med."},{"key":"38430_CR51","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1055\/s-0034-1375962","volume":"34","author":"A Regev","year":"2014","unstructured":"Regev, A. Drug-induced liver injury and drug development: industry perspective. Semin Liver Dis. 34, 227\u2013239 (2014).","journal-title":"Semin Liver Dis."},{"key":"38430_CR52","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nrc1970","volume":"6","author":"ME Lacouture","year":"2006","unstructured":"Lacouture, M. E. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat. Rev. Cancer 6, 803\u2013812 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"38430_CR53","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1093\/cvr\/cvz022","volume":"115","author":"J Versmissen","year":"2019","unstructured":"Versmissen, J., Mirabito Colafella, K. M., Koolen, S. L. W. & Danser, A. H. J. Vascular cardio-oncology: vascular endothelial growth factor inhibitors and hypertension. Cardiovasc. Res. 115, 904\u2013914 (2019).","journal-title":"Cardiovasc. Res."},{"key":"38430_CR54","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","volume":"44","author":"L Spain","year":"2016","unstructured":"Spain, L., Diem, S. & Larkin, J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat. Rev. 44, 51\u201360 (2016).","journal-title":"Cancer Treat. Rev."},{"key":"38430_CR55","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.ejmech.2019.06.070","volume":"179","author":"F Chen","year":"2019","unstructured":"Chen, F. et al. Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma. Eur. J. Med. Chem. 179, 916\u2013935 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"38430_CR56","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s40264-013-0048-4","volume":"36","author":"RR Shah","year":"2013","unstructured":"Shah, R. R., Morganroth, J. & Shah, D. R. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf. 36, 491\u2013503 (2013).","journal-title":"Drug Saf."},{"key":"38430_CR57","doi-asserted-by":"publisher","first-page":"6910","DOI":"10.1158\/0008-5472.CAN-05-0530","volume":"65","author":"CN Landen Jr.","year":"2005","unstructured":"Landen, C. N. Jr. et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65, 6910\u20136918 (2005).","journal-title":"Cancer Res."},{"key":"38430_CR58","doi-asserted-by":"publisher","first-page":"e53528","DOI":"10.1371\/journal.pone.0053528","volume":"8","author":"J Thundyil","year":"2013","unstructured":"Thundyil, J. et al. Evidence that the EphA2 receptor exacerbates ischemic brain injury. PLoS One 8, e53528 (2013).","journal-title":"PLoS One"},{"key":"38430_CR59","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1161\/CIRCULATIONAHA.116.026644","volume":"136","author":"AC Finney","year":"2017","unstructured":"Finney, A. C. et al. EphA2 expression regulates inflammation and fibroproliferative remodeling in atherosclerosis. Circulation 136, 566\u2013582 (2017).","journal-title":"Circulation"},{"key":"38430_CR60","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1165\/rcmb.2011-0044OC","volume":"46","author":"TC Carpenter","year":"2012","unstructured":"Carpenter, T. C., Schroeder, W., Stenmark, K. R. & Schmidt, E. P. Eph-A2 promotes permeability and inflammatory responses to bleomycin-induced lung injury. Am. J. Respir. Cell Mol. Biol. 46, 40\u201347 (2012).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"38430_CR61","doi-asserted-by":"publisher","first-page":"5334","DOI":"10.1096\/fj.201801519RR","volume":"33","author":"Y Kaibori","year":"2019","unstructured":"Kaibori, Y., Saito, Y. & Nakayama, Y. EphA2 phosphorylation at Ser897 by the Cdk1\/MEK\/ERK\/RSK pathway regulates M-phase progression via maintenance of cortical rigidity. FASEB J. 33, 5334\u20135349 (2019).","journal-title":"FASEB J."},{"key":"38430_CR62","doi-asserted-by":"publisher","unstructured":"Gravina, G. L. et al. The small molecule ephrin receptor inhibitor, GLPG1790, reduces renewal capabilities of cancer stem cells, showing anti-tumour efficacy on preclinical glioblastoma models. Cancers 11, https:\/\/doi.org\/10.3390\/cancers11030359 (2019).","DOI":"10.3390\/cancers11030359"},{"key":"38430_CR63","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1007\/s12072-020-10068-4","volume":"14","author":"X Zhang","year":"2020","unstructured":"Zhang, X. et al. Silencing of functional p53 attenuates NAFLD by promoting HMGB1-related autophagy induction. Hepatol. Int. 14, 828\u2013841 (2020).","journal-title":"Hepatol. Int."},{"key":"38430_CR64","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/path.2637","volume":"220","author":"M Hollstein","year":"2010","unstructured":"Hollstein, M. & Hainaut, P. Massively regulated genes: the example of TP53. J. Pathol. 220, 164\u2013TP173 (2010).","journal-title":"J. Pathol."},{"key":"38430_CR65","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.molmed.2009.09.005","volume":"15","author":"JD Amaral","year":"2009","unstructured":"Amaral, J. D., Castro, R. E., Steer, C. J. & Rodrigues, C. M. p53 and the regulation of hepatocyte apoptosis: implications for disease pathogenesis. Trends Mol. Med. 15, 531\u2013541 (2009).","journal-title":"Trends Mol. Med."},{"key":"38430_CR66","doi-asserted-by":"publisher","first-page":"6048","DOI":"10.1073\/pnas.94.12.6048","volume":"94","author":"M Fiscella","year":"1997","unstructured":"Fiscella, M. et al. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc. Natl Acad. Sci. USA 94, 6048\u20136053 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"38430_CR67","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1073\/pnas.0712216105","volume":"105","author":"Y Abe","year":"2008","unstructured":"Abe, Y. et al. Hedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2. Proc. Natl Acad. Sci. USA 105, 4838\u20134843 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"38430_CR68","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1055\/s-2007-969504","volume":"51","author":"Y Kiso","year":"1985","unstructured":"Kiso, Y., Tohkin, M., Hikino, H., Ikeya, Y. & Taguchi, H. Mechanism of antihepatotoxic activity of wuweizisu C and gomisin A1. Planta Med. 51, 331\u2013334 (1985).","journal-title":"Planta Med."},{"key":"38430_CR69","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1254\/fpj.85.193","volume":"85","author":"S Takeda","year":"1985","unstructured":"Takeda, S. et al. [Pharmacological studies on schizandra fruits. III. Effects of wuweizisu C, a lignan component of schizandra fruits, on experimental liver injuries in rats]. Nihon Yakurigaku Zasshi 85, 193\u2013208 (1985).","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"38430_CR70","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2174\/157340609787049316","volume":"5","author":"GT Liu","year":"2009","unstructured":"Liu, G. T. Bicyclol: a novel drug for treating chronic viral hepatitis B and C. Med. Chem. 5, 29\u201343 (2009).","journal-title":"Med. Chem."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-38430-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-38430-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-38430-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T08:07:51Z","timestamp":1684138071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-38430-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,13]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["38430"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-38430-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2159741\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,13]]},"assertion":[{"value":"12 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2756"}}